BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth
US6537804B1 · kind B1 · utility
1Cited by
4References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 1999 |
| Grant date | Mar 25, 2003 |
| Priority date | — |
| Expiry date | Jun 21, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for detecting and quantitating BCR-ABL gene products and other abnormal ABL gene products of Ph1-positive leukemic cells. The invention further provides methods for determining the relative number of leukemic cells compared with normal ABL cells to assess the tumor burden of a patient. In another aspect, the methods of the present invention can be used to determine a specific phase of leukemia, particularly chronic-phase CML.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.